BioWorld - Sunday, January 11, 2026

Analysis and data insight
Analysis and data insight RSS Feed RSS

Dollar sign, downward arrow

Biopharma equities caught in vortex of oil crash and coronavirus fears

March 9, 2020
By Peter Winter
The financial markets were delivered a one-two punch March 9 – a plunge in oil prices along with fears that the coronavirus is continuing to spread unabated. As a result, the Dow Jones Industrial Average cratered 1,500 points in early trading after a brief halt with market circuit breakers kicking in. Biopharma equities did not escape the carnage, with the BioWorld Biopharmaceutical index trading down about 4% by market close, with the Dow closing down 7.8%.
Read More
Wall Street sign

Completed and pending biopharma IPOs in February 2020

March 6, 2020
Completed and pending initial public offerings by biopharma companies, including: 4D Molecular, Akeso, Beam, Bio-Thera, Continent, Frontier, Hutchison China Meditech, Imara, Immunotech, Innocare, NLS, Oric, Passage Bio, Revolution Medicines, Scilex, Shanghai Shenlian, Tasly.
Read More

Follow-on offerings of biopharma companies in February 2020

March 6, 2020
Follow-ons completed by biopharma companies, including: Adma, Adverum, Agile, Appili, Applied Genetic Technologies, Atyr, Avrobio, Axovant Gene, Bioxcel, Briacell, Can-Fite, Catalyst, Collegium, Deciphera, Diamedica, Eyepoint, Fortress, Intec, Kezar Life Sciences, Miragen, Moderna, Novan, Oramed, PDS, Phio, Polarityte, Rapt, Rockwell Medical, Salarius, Seelos, Theravance, Tonix, Xeris, Ziopharm, Zosano.
Read More

Other financings of public biotechnology companies in February 2020

March 6, 2020
Private placements and other private financings of public biopharma companies, including: Acerus, Adamis, Aeterna Zentaris, Agile, Algernon, Alimera, Aptorum, Arch, Armata, Avadel, Biomerica, Cidara, Cocrystal, Collegium, Collplant, Cortexyme, CTI, Curis, Daré, Enlivex, E-therapeutics, Genmab, Genprex, Hemostemix, Kali-Extracts, Lidds, Lipocine, Mereo, Moleculin, Navidea, Novacyt, Orphazyme, Outlook, Phio, Promis, Redhill, Redx, Revance, Revive, Spero, Syndax, Syros, Valneva, Vaxil, Xortx, Zelira.
Read More

Venture capital and other private biopharma financings in February 2020

March 6, 2020
Venture capital and other private financings of private biopharma companies, including: Aivita, Alladapt, Alx Oncology, Aurora Science, Azafaros, Canbridge, Ikarovec, Inotrem, Kahr Medical, Kaipharm, Maat Pharma, Neotx, Novelty Nobility, Omass, Oncodna, Pentixapharm, Pinpoint, Sonoma, Spruce Biosciences, Valo, Volastra.
Read More